PRKG2 Antikörper (C-Term)

Produktnummer ABIN392537

Es sind 4+ Publikationen für dieses Produkt verfügbar. Der Kaninchen Polyklonal anti-PRKG2 Antikörper wird verwendet zum Nachweis von PRKG2 in Proben von Human. Er wurde validiert für WB und IHC (p).

Kurzübersicht für PRKG2 Antikörper (C-Term) (ABIN392537)

Target: PRKG2 (Protein Kinase, CGMP-Dependent, Type II (PRKG2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PRKG2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: RB01036

Produktdetails anti-PRKG2 Antikörper

Bindungsspezifität: AA 714-744, C-Term

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This cGKII antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 714-744 amino acids from the C-terminal region of human cGKII.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000. IHC-P: 1:50~100. IHC-P: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Haltbarkeit: 6 months

Referenzen für anti-PRKG2 Antikörper (ABIN392537)

Zhu, Yao, Wu, Qian, Wu, Chen: "Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells." in: Molecular medicine reports, Vol. 13, Issue 2, pp. 1909-13, (2016) (PubMed).

Yao, Wu, Zhu, Qian, Chen et al.: "Nitric oxide/cyclic guanosine monophosphate inducers sodium nitroprusside and L-arginine inhibit the proliferation of gastric cancer cells via the activation of type II cyclic guanosine ..." in: Oncology letters, Vol. 10, Issue 1, pp. 479-484, (2015) (PubMed).

Jiang, Wu, Wu, Lan, Wang, Qian, Chen: "Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines." in: Oncology letters, Vol. 9, Issue 6, pp. 2781-2786, (2015) (PubMed).

Rangaswami, Marathe, Zhuang, Chen, Yeh, Frangos, Boss, Pilz: "Type II cGMP-dependent protein kinase mediates osteoblast mechanotransduction." in: The Journal of biological chemistry, Vol. 284, Issue 22, pp. 14796-808, (2009) (PubMed).

Details zu PRKG2

Target: PRKG2 (Protein Kinase, CGMP-Dependent, Type II (PRKG2))

Andere Bezeichnung: cGKII

Hintergrund: CGKII is thought to play a key role in a diverse set of physiological pathway. cGKII may mediate intestinal secretion of water and electrolytes induced by the E. coli toxin STa and the intestinal peptide guanylin. Edentification of the pathway that mediates intestinal fluid secretion by E. coli STa has potential medical implications because STa causes traveler's diarrhea and about 50 % of infant mortality in developing countries. Transfection experiments in human cells disclose that cGKII phosphorylates SOX9 and attenuates SOX9 function by inhibiting its nuclear entry. Impaired differentiation of cultured KMI chondrocytes can be restored by silencing Sox9 by RNA interference. cGKII is postulated to be a molecular switch that couples the cessation of proliferation and the start of hypertrophic chondrocyte differentiation through attenuating SOX9 function.

Molekulargewicht: 87432

Gen-ID: 5593

NCBI Accession: NP_006250

UniProt: Q13237